The NANOKINOME project focusses on the development of nanosensors for drug target deconvolution. In particular, Teresa works on the development of a fluorescent and magnetic nanosensor to detect the different targets of promiscuous kinase inhibitors and other anticancer drugs with the final objective of avoiding those responsible for side effects. The project is divided in two phases: a first phase dedicated to the validation of the nanoprobe for target deconvolution and a second phase dedicated to the addition of several functional moieties for the improvement of the probe performance. The project, which has a duration of 24 months is funded by the TALENTIA POSTDOC FELLOWSHIP PROGRAM (267226). “This project has received funding from the European Union¿s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 267226”.

Teresa studied Pharmacy at the University of Granada (UGR). After finishing her Master Degree on the discovery of novel neuroprotective drugs for Alzheimer Disease at the Autonomous University of Madrid (UAM), she performed her doctoral studies in the framework of the FP6-RTN project Cellcheck as ESR. Her project focussed on the development of novel applications of impedimetric biosensors for neurobiology and cancer research. She obtained her PhD in 2013 from the Institut of Microsystems Engineering (IMTEK) of the University of Freiburg as a result of the multidisciplinary collaboration among this University and the Faculty of Biotechnology of the University of Athens (AUA).

Additionally, she worked as principal researcher in the FP7-SME project Foodscan in one of the SMEs involved for the development of a novel biosensor for the small food industry. She also worked as executive guest editor for the journal Current Pharmaceutical Design.

She received a FP7 co-fund postdoctoral fellowship from the Talentia Postdoc program for the Nanokinome project at the Nanochembio group of the Department of Organic Chemistry at the University of Granada. Currently, she is performing a yearly secondment at the Cancer Research UK Edinburgh Center. Her project focusses on nanosensor design for drug target deconvolution.